Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Hemab Therapeutics logo — The next generation of therapeutics for bleeding and thrombo...

Hemab Therapeutics

The next generation of therapeutics for bleeding and thrombotic disorders

Founded 2020 Denmark Denmark 114 employees Series B Total: $190.00M Biotechnology, Life Sciences +1

General Information

Company Name Hemab Therapeutics
Founded Year 2020
Location Denmark Denmark
Founders / Decision Makers
Team member
Employees 114
Industries Biotechnology, Life Sciences, Pharmaceutical
Funding Stage Series B
Business Model B2B, B2B2C
Revenue Model Product Sales, Licensing, Value Based Pricing
Social

BounceWatch is an independent company data service, not affiliated with Hemab Therapeutics. To contact Hemab Therapeutics, visit hemab.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Hemab Therapeutics compare?

A PDF of Hemab Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Hemab Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Hemab Therapeutics

Hemab Therapeutics, founded in 2020, is a clinical-stage biotech company specializing in the development of prophylactic therapeutics for bleeding and thrombotic disorders. With headquarters in both Cambridge, Massachusetts and Copenhagen, Denmark, Hemab is dedicated to transforming the treatment landscape for patients with high unmet medical needs.

Positioning itself at the forefront of therapeutic innovation, Hemab's strategic initiative, Hemab 1-2-5, aims to deliver 5 clinical assets by 2025. The company focuses on monoclonal and bispecific antibody-based therapeutics targeting disorders including Glanzmann Thrombasthenia, factor VII deficiency, and Von Willebrand Disease.

The company recently secured a $135.00M Series B investment on February 21, 2023. Major investors include Novo Holdings, Maj Invest Private Equity, RA Capital Management, and others. This substantial capital injection underscores confidence in Hemab's mission to drive innovation in a highly specialized sector.

Business keywords: therapeutics, bleeding disorders, thrombotic disorders, monoclonal antibodies, bispecific antibodies, prophylactic treatments, Glanzmann Thrombasthenia, factor VII deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, clinical-stage development, innovative healthcare, hemostatic therapy, unmet medical needs

Services & Products

Developing therapies for bleeding disorders
Conducting clinical trials
Research in blood coagulation disorders
Providing educational resources

Target Customers

Patients with bleeding disorders Caregivers Healthcare providers Investors Medical researchers

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $135.00M 9
Novo Holdings Maj Invest Private Equity RA Capital Management
Novo Holdings, Maj Invest Private Equity +7
21 Feb 2023
Series A $55.00M 1
RA Capital Management
RA Capital Management
22 Jul 2021
Seed Round Undisclosed 1
Novo Holdings
Novo Holdings
14 Dec 2020

Latest News

View All
22 techbio soonicorns ready to cross the $1bn threshold — Sifted
22 techbio soonicorns ready to cross the $1bn threshold
Sifted Feb 22, 2024

Hemab Therapeutics Alternatives & Competitors

View All Alternatives
Hemab Therapeutics vs
Genmab
Genmab Denmark

Differentiated human antibody therapeutics for the treatment of cancer

IPO
3102 employees
Biotechnology, Pharmaceutical
Compare Hemab Therapeutics vs Genmab
Hemab Therapeutics vs
CytoAgents, Inc
CytoAgents, Inc United States

Calming the Cytokine Storm, Rebalancing the Immune System. Accessible treatment for multiple areas...

Series A
10 employees
Biotechnology, Health Care
Compare Hemab Therapeutics vs CytoAgents, Inc
Hemab Therapeutics vs
IXALTIS SA
IXALTIS SA France

DEVELOPING INNOVATIVE TREATMENTS FOR GENITOURINARY TRACT DISORDERS

Venture round
2 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Hemab Therapeutics

The next generation of therapeutics for bleeding and thrombotic disorders
Hemab Therapeutics was founded in 2020.
Hemab Therapeutics is headquartered in Denmark.
Hemab Therapeutics operates in Biotechnology, Life Sciences and Pharmaceutical. Its work centres on therapeutics, bleeding disorders, thrombotic disorders and monoclonal antibodies. Its customers include Patients with bleeding disorders, Caregivers and Healthcare providers.
Hemab Therapeutics has a B2B and B2B2C business model. Its revenue comes from Product Sales, Licensing and Value Based Pricing.
Hemab Therapeutics has approximately 114 employees.
Hemab Therapeutics has completed 3 funding rounds, raising a total of $190.00M. The latest funding stage is Series B.
Hemab Therapeutics offers: Developing therapies for bleeding disorders, Conducting clinical trials, Research in blood coagulation disorders, Providing educational resources.
Top alternatives and competitors to Hemab Therapeutics include Genmab, CytoAgents, Inc, IXALTIS SA, Calluna Pharma, Ocuphire Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Hemab Therapeutics and Genmab are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Hemab Therapeutics, https://bouncewatch.com/company/hemab-therapeutics, updated 5 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout